Trial Profile
A Randomised, Double-blind, Placebo-controlled Trial Assessing the Efficacy of SLITone in House Dust Mite Allergic Patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic asthma; Rhinoconjunctivitis
- Focus Therapeutic Use
- 13 Feb 2010 New trial record